.6B, trading at

Full research coverage

Frequently Asked Questions

What is Cellebrite DI's market cap?

Cellebrite DI (CLBT) has a market capitalization of approximately

.6B, trading at

What is Cellebrite DI's P/E ratio?

Cellebrite DI's trailing twelve-month P/E ratio is 48.9x, with a price-to-book (P/B) of 6.9x. Valuation multiples are best compared with Technology sector peers rather than read in isolation.

How profitable is Cellebrite DI?

Cellebrite DI runs a net profit margin of 14.5%, a gross margin of 83.9%, and an operating margin of 12.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Cellebrite DI generate?

Cellebrite DI reported revenue of $476M for fiscal year 2025, with net income of $78M and earnings per share (EPS) of 0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Cellebrite DI pay a dividend?

Cellebrite DI does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Cellebrite DI financially healthy?

Cellebrite DI carries a debt-to-equity ratio of 0.04x and a current ratio of 1.53x, with a market beta of 1.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Cellebrite DI a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cellebrite DI (CLBT) the key facts are: market cap

.6B, P/E 48.9x, revenue $476M, 52-week range 11.02-19.98. Weigh valuation, profitability, growth, and balance-sheet strength against Technology peers and form your own view.

Track Cellebrite DI's full fundamentals live

Get Cellebrite DI's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.